Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06289686 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rotator Cuff Repairs With or Without BioEnthesis™ Augmentation

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
    • Primary and study completion dates: Dec 2025 to Aug 2027
    • Study sites: 2 to 5
    • Start date changed from estimate of Jul 2024 to Jul 28, 2023
    • Eligibility criteria expanded, about 13 words
    • Collaborators: 2 to 1
    • Study title shortened, about 4 words
  2. Notable Start date: Mar 2024 to Jul 2024
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised at 2 of 2 sites
    v3
  3. Minor Start date: Feb 2024 to Mar 2024v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Rotator cuff (RC) injuries are particularly prevalent, difficult to repair, and attachment between the bone and tendon is notoriously difficult to achieve. The most common method and current standard of care (SOC) for reattaching connective tissues (e.g., ligaments, tendons) to bone typically involves suture anchor-based techniques, but this is fraught with problems. More specifically, re-tearing of the connective tissue after this procedure occurs in 30-60% of cases, and can be even higher in patients who engage in smoking, have a diagnosis of diabetes, etc. To address these clinical challenges, Sparta Biopharma Inc. (Sparta) developed a unique technology, called BioEnthesis, to improve the connection between the tendon and bone. Pre-clinical in vivo studies demonstrated that the biphasic bovine cancellous matrix regenerated at the bone-soft tissue interface-thereby leading to high structural integrity and will likely lead to reduced re-tear rates over time. The investigators hypothesize that patients in this interventional cohort will experience enhanced mobility, reduced pain, and less re-tears after RC procedures versus a standard suture anchor-based repair.
Trial Details
NCT Number NCT06289686
Lead Sponsor Brooke Army Medical Center
Collaborators: Sparta Biopharma
Conditions
(from sponsor)
Rotator Cuff Tears, Rotator Cuff Injuries, Surgery
Related terms Rotator Cuff Injuries
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov